HIV Prevention in a Time of COVID-19: A Report from the HIVR4P // Virtual Conference 2021

AIDS Res Hum Retroviruses. 2022 May;38(5):350-358. doi: 10.1089/AID.2021.0138. Epub 2021 Nov 25.


The HIV Research for Prevention (HIVR4P) conference catalyzes knowledge sharing on biomedical HIV prevention interventions such as HIV vaccines, antibody infusions, pre-exposure prophylaxis, and microbicides in totality-from the molecular details and delivery formulations to the behavioral, social, and structural underpinnings. HIVR4P // Virtual was held over the course of 2 weeks on January 27-28 and February 3-4, 2021 as the coronavirus disease 2019 (COVID-19) pandemic continued to inflict unprecedented harm globally. The HIVR4P community came together with 1,802 researchers, care providers, policymakers, implementers, and advocates from 92 countries whose expertise spanned the breadth of the HIV prevention pipeline from preclinical to implementation. The program included 113 oral and 266 poster presentations. This article presents a brief summary of the conference highlights. Complete abstracts, webcasts, and daily rapporteur summaries may be found on the conference website (

Keywords: HIV; HIVR4P; PrEP; South Africa; TaSP; antiretrovirals; broadly neutralizing antibodies (bNAbs); clinical trials; microbicides; prevention; vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines*
  • Anti-HIV Agents* / therapeutic use
  • COVID-19* / prevention & control
  • HIV Infections* / drug therapy
  • HIV Infections* / epidemiology
  • HIV Infections* / prevention & control
  • Health Services Research
  • Humans
  • Pre-Exposure Prophylaxis*


  • AIDS Vaccines
  • Anti-HIV Agents